P51.06 Outcomes of First-Line TKI Treated Advanced NSCLC with Distinct Types of EGFR Mutations: Brain Metastasis and De Novo T790M

The clinical features, survival outcomes and patterns of treatment failure of advanced non-small cell lung cancer (NSCLC) patients harboring distinct subtypes of EGFR mutations and receiving first-line EGFR tyrosine kinases inhibitor (TKIs) are not fully understood.